We are currently looking for a Postdoctoral Scientist within the Tumour Suppressors Group. In this group we aim to understand the role of p53 and mutations in p53 in small cell lung cancer and the interplay with other tumour suppressors. We are particularly interested in which mutations correlate with worse outcome and to what extent p53 mutations contribute to chemoresistance and the aggressiveness of this disease. Previously, we discovered a role for mutant p53 in regulating rab coupling protein (RCP) recycling of integrins and growth factor receptors in invasion and metastasis. Preliminary data in the lab indicates that not only integrins and growth factor receptors are regulated, but also drug transporters. This would make RCP an interesting drug target to prevent metastasis and to make tumours more sensitive to current chemotherapeutics.
The post holder will investigate the role of RCP in small cell lung cancer by checking expression levels in patient samples, mutation status and the role of RCP in chemoresistance of small cell lung cancer primary tumour cells. They will characterize the interaction between RCP and drug transporters and work together with a small company to investigate the potential of small molecule inhibitors to prevent RCP from binding to those drug transporters. Any potential candidate molecules will be tested in a variety of cell lines, primary tumour samples and in xenograft in vivo experiments.
The successful applicant should have a PhD in Cell Biology, Molecular Biology, Medial Biology, Oncology, or a related field. Experience in cell culture, cell signalling pathways and molecular biology is essential. Whilst experience with primary cell lines and in vivo modelling is not required, it is desirable.
For any informal enquiries about this post, please contact Dr Patricia Muller via email:
[email protected]The Cancer Research UK Manchester Institute (
www.cruk.manchester.ac.uk), an Institute of The University of Manchester (
www.manchester.ac.uk), is a world-leading centre for excellence in cancer research. The Institute is core funded by Cancer Research UK (
www.cancerresearchuk.org), the largest independent cancer research organisation in the world. We are currently situated at the internationally-renowned life sciences campus at Alderely Park in Cheshire England, 15 miles from Manchester, a vibrant and dynamic city surrounded by beautiful countryside.
We are partnered with The Christie NHS Foundation Trust (adjacent to the CRUK MI Paterson Building) in South Manchester (
www.christie.nhs.uk), one of the largest cancer treatment centres in Europe. These factors combine to provide an exceptional environment in which to pursue basic, translational and clinical research programmes.
To apply for this position please visit our website:
www.cruk.manchester.ac.uk
